ADOCIA SAS (ADOC.PA)
FR0011184241 - Common Stock
We assign a fundamental rating of 2 out of 10 to ADOC. ADOC was compared to 76 industry peers in the Biotechnology industry. ADOC has a bad profitability rating. Also its financial health evaluation is rather negative. ADOC has a valuation in line with the averages, but on the other hand it scores bad on growth.
1. Profitability
1.1 Basic Checks
ADOC had negative earnings in the past year.
ADOC had a negative operating cash flow in the past year.
ADOC had negative earnings in each of the past 5 years.
ADOC had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -84.80%, ADOC is doing worse than 78.87% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -84.8% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-61.02%
ROA(5y)-52.94%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ADOC has a better Gross Margin (64.42%) than 69.01% of its industry peers.
ADOC does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 64.42% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ADOC does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ADOC has more shares outstanding
ADOC has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, ADOC has an improved debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -1.72, we must say that ADOC is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -1.72, ADOC is doing worse than 61.97% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.72 |
ROIC/WACCN/A
WACC7.82%
2.3 Liquidity
A Current Ratio of 1.02 indicates that ADOC should not have too much problems paying its short term obligations.
ADOC's Current ratio of 1.02 is on the low side compared to the rest of the industry. ADOC is outperformed by 77.46% of its industry peers.
A Quick Ratio of 1.01 indicates that ADOC should not have too much problems paying its short term obligations.
ADOC has a Quick ratio of 1.01. This is in the lower half of the industry: ADOC underperforms 69.01% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.02 | ||
| Quick Ratio | 1.01 |
3. Growth
3.1 Past
ADOC shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -148.31%.
Looking at the last year, ADOC shows a very negative growth in Revenue. The Revenue has decreased by -81.22% in the last year.
ADOC shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -46.13% yearly.
EPS 1Y (TTM)-148.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%32.04%
Revenue 1Y (TTM)-81.22%
Revenue growth 3Y36.74%
Revenue growth 5Y-46.13%
Sales Q2Q%-87.24%
3.2 Future
ADOC is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 0.53% yearly.
Based on estimates for the next years, ADOC will show a very strong growth in Revenue. The Revenue will grow by 23.43% on average per year.
EPS Next Y47.15%
EPS Next 2Y15.82%
EPS Next 3Y0%
EPS Next 5Y0.53%
Revenue Next Year68.06%
Revenue Next 2Y35.4%
Revenue Next 3Y31.04%
Revenue Next 5Y23.43%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
ADOC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 1.48, the valuation of ADOC can be described as very cheap.
Based on the Price/Forward Earnings ratio, ADOC is valued cheaply inside the industry as 97.18% of the companies are valued more expensively.
The average S&P500 Price/Forward Earnings ratio is at 21.22. ADOC is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 1.48 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.82%
EPS Next 3Y0%
5. Dividend
5.1 Amount
No dividends for ADOC!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ADOCIA SAS
EPA:ADOC (9/6/2024, 7:00:00 PM)
5.46
-0.02 (-0.36%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap82.12M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 1.48 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -84.8% | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 64.42% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.09
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.02 | ||
| Quick Ratio | 1.01 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-148.31%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y47.15%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-81.22%
Revenue growth 3Y36.74%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y